Ozempic and Wegovy both contain semaglutide, but a useful US cost comparison begins with their different prescriptions. Route, indication, device and insurance eligibility matter more than comparing two advertised minimum prices.
| Comparison point | Ozempic | Wegovy |
|---|---|---|
| Ingredient | Semaglutide | Semaglutide |
| Current forms | Weekly injection and separate daily tablets | Weekly injection and daily tablets; current injection presentations include HD |
| Approved uses | Adult type 2 diabetes and specified cardiovascular uses; injection also has a kidney indication in adults with type 2 diabetes and chronic kidney disease | Weight management and specified cardiovascular uses; injection also has accelerated approval for certain adults with MASH |
| What a quote must name | Route, dose, device or tablet strength, quantity and supply | Route, strength, device, treatment stage, quantity and supply |
| Why a headline can mislead | A pen offer may not describe a tablet prescription or continuing fill | An introductory or device-specific offer may not describe maintenance treatment |
| Substitution | A clinician-directed product or route change requires new instructions | Shared semaglutide does not establish direct substitution |
Are both medicines suitable for the treatment goal?
Ozempic injection, Ozempic tablets and Wegovy formulations have different approved uses. Treatment for type 2 diabetes, weight management, cardiovascular risk or metabolic dysfunction-associated steatohepatitis (MASH) can raise different clinical and coverage questions. Ask the prescriber which options are suitable before comparing their cost.
Match route, device and continuing supply
A weekly multidose pen, a pack of single-dose devices and a bottle of daily tablets are different units of comparison. Request the actual prescribed strength, scheduled doses and billed days for each. If a clinician considers both options appropriate, compare the same period of continuing treatment, not one product’s starter pack against another product’s maintenance supply.
Check coverage for each prescription
Ask for formulary status and any authorization requirements for each exact product and use. Coverage of one semaglutide brand or route does not guarantee another. Check whether the payment reflects the deductible, a copay, coinsurance or a noncovered cash transaction. Write down any required pharmacy and the quote date.
Check each NovoCare offer separately
NovoCare offers differ by product and payment method. Check eligible insurance, route, dose, supply, time limits and the next fill’s terms. A commercial savings card and a self-pay arrangement are different benefits. An introductory amount may not continue, and a link to another product’s offer does not establish eligibility for that product.
Finding detailed self-pay prices
The Ozempic and Wegovy cost-without-insurance guides linked below provide detailed self-pay information. Confirm current official terms for the prescribed presentation. To compare quotes, check the treatment purpose, coverage decision and supply period for each.
Comparing your total payments
For each suitable option, write down the payment, days’ supply, separate device or visit charges, offer eligibility and expected next-fill terms. The lower-cost choice may differ between people and insurance plans. Do not combine semaglutide products; ask the clinical team for instructions if changing treatment.
Questions and answers
Is Wegovy automatically cheaper because it is marketed for weight management?
No. Personal cost depends on the exact formulation, plan and eligible payment pathway.
Can an Ozempic injection authorization cover Wegovy tablets?
Do not assume so. Product, route and indication must be checked separately.
Should I compare introductory prices?
Write down introductory amounts separately from ongoing costs, including their time, dose and eligibility conditions.
Are these medicines interchangeable because they share semaglutide?
Not by that assumption. A product or route change requires a clinician’s instructions and a new coverage check.
Related reading
Sources
- Ozempic: official US prescribing information
- Novo Nordisk: Rybelsus and Ozempic tablets prescribing information
- Ozempic: official manufacturer support and current terms
- HealthCare.gov: prescription coverage, formularies and exceptions
- FDA: generic drug facts
- Wegovy: official US prescribing information
- Wegovy: official manufacturer support and current terms
Sources checked 1 October 2026. This information does not replace advice from your healthcare professional. For complete warnings and instructions, read the product information and consult the prescribing team.
Reviewed by: Mattias Hagman, PhD
About the reviewer:
Dr Mattias Hagman (PhD, University of Sydney) has an academic background and experience working with healthcare-related content and regulated industries. He has lecturing experience at international universities, including Stockholm University and the University of Malta.
Last reviewed: October 2026